Teva and Alvotech are introducing Selarsdi at an 85% discount off the reference product Stelara. Selarsdi is available as a subcutaneous injection and for intravenous infusion.
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...
Blue Cross Blue Shield (BCBS), under its parent company Health Care Service Corporation, is changing how certain asthma injections are administered.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback